This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ratech, H. Articles by Hirschhorn, R. Search for Related Content PubMed PubMed Citation Articles by Ratech, H. Articles by Hirschhorn, R.

American Journal of Pathology, Vol 120, 157-169, Copyright © 1985 by American Society for Investigative Pathology

REGULAR ARTICLES

Pathologic findings in adenosine deaminase-deficient severe combined immunodeficiency. I. Kidney, adrenal, and chondro-osseous tissue alterations

H Ratech, MA Greco, G Gallo, DL Rimoin, H Kamino and R Hirschhorn

The authors have reviewed the autopsies of 8 patients with adenosine- deaminase-deficient severe combined immunodeficiency disease (ADA- SCID). Several new findings in nonlymphoid organs, including kidney and adrenal gland, and chondro-osseous tissue indicate the multisystem nature of this disorder. Examination of renal tissue in 7 of 8 cases showed mesangial sclerosis. This was confirmed in 3 cases by electron microscopy. One case, treated with multiple erythrocyte partial exchange transfusions for several years, had no mesangial sclerosis. Six of 8 cases showed adrenal-gland cortical sclerosis. Chondro-osseous tissue from vertebrae and costochondral junctions of 4 cases examined showed typical alterations previously reported in ADA-SCID such as short growth plates with few proliferating and some hypertrophic chondrocytes. The authors report the new observations of necrotic chondrocytes, as well as large amounts of cellular debris. These changes were not observed in the 2 other patients examined, who received bone marrow or multiple partial exchange transfusions. The distribution and severity of these lesions, their relationship to ADA replacement therapy, and their homology to mice treated with a potent ADA inhibitor suggests that, in addition to lymphoid dysfunction, disordered nucleoside metabolism due to absent ADA activity in ADA-SCID may be the cause of diverse multi-system pathologic changes in tissues which continue to differentiate or mature after birth.

This article has been cited by other articles:

				P. Titman, E. Pink, E. Skucek, K. O'Hanlon, T. J. Cole, J. Gaspar, J. Xu-Bayford, A. Jones, A. J. Thrasher, E. G. Davies, et al. Cognitive and behavioral abnormalities in children after hematopoietic stem cell transplantation for severe congenital immunodeficiencies Blood, November 1, 2008; 112(9): 3907 - 3913. [Abstract] [Full Text] [PDF]

				A. Mortellaro, R. J. Hernandez, M. M. Guerrini, F. Carlucci, A. Tabucchi, M. Ponzoni, F. Sanvito, C. Doglioni, C. D. Serio, L. Biasco, et al. Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects Blood, November 1, 2006; 108(9): 2979 - 2988. [Abstract] [Full Text] [PDF]

				D. A. Kaufman, M. S. Hershfield, J. A. Bocchini, I. J. Moissidis, M. Jeroudi, and S. L. Bahna Cerebral Lymphoma in an Adenosine Deaminase-Deficient Patient With Severe Combined Immunodeficiency Receiving Polyethylene Glycol-Conjugated Adenosine Deaminase Pediatrics, December 1, 2005; 116(6): e876 - e879. [Abstract] [Full Text] [PDF]

				F. X. Arredondo-Vega, I. Santisteban, E. Richard, P. Bali, M. Koleilat, M. Loubser, A. Al-Ghonaium, M. Al-Helali, and M. S. Hershfield Adenosine deaminase deficiency with mosaicism for a "second-site suppressor" of a splicing mutation: decline in revertant T lymphocytes during enzyme replacement therapy Blood, February 1, 2002; 99(3): 1005 - 1013. [Abstract] [Full Text] [PDF]

				M. R. Blackburn, J. B. Volmer, J. L. Thrasher, H. Zhong, J. R. Crosby, J. J. Lee, and R. E. Kellems Metabolic Consequences of Adenosine Deaminase Deficiency in Mice Are Associated with Defects in Alveogenesis, Pulmonary Inflammation, and Airway Obstruction J. Exp. Med., July 10, 2000; 192(2): 159 - 170. [Abstract] [Full Text] [PDF]

				M. R. Blackburn, S. K. Datta, and R. E. Kellems Adenosine Deaminase-deficient Mice Generated Using a Two-stage Genetic Engineering Strategy Exhibit a Combined Immunodeficiency J. Biol. Chem., February 27, 1998; 273(9): 5093 - 5100. [Abstract] [Full Text] [PDF]

				M. E. Bollinger, F. X. Arredondo-Vega, I. Santisteban, K. Schwarz, M. S. Hershfield, and H. M. Lederman Hepatic Dysfunction as a Complication of Adenosine Deaminase Deficiency N. Engl. J. Med., May 23, 1996; 334(21): 1367 - 1372. [Full Text] [PDF]

				M. R. Blackburn, M. Aldrich, J. B. Volmer, W. Chen, H. Zhong, S. Kelly, M. S. Hershfield, S. K. Datta, and R. E. Kellems The Use of Enzyme Therapy to Regulate the Metabolic and Phenotypic Consequences of Adenosine Deaminase Deficiency in Mice. DIFFERENTIAL IMPACT ON PULMONARY AND IMMUNOLOGIC ABNORMALITIES J. Biol. Chem., October 6, 2000; 275(41): 32114 - 32121. [Abstract] [Full Text] [PDF]